PMID- 25967686
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151026
LR  - 20150513
IS  - 0873-2159 (Print)
IS  - 0873-2159 (Linking)
VI  - 14 Suppl 3
DP  - 2008 Oct
TI  - Treatment of advanced non small cell lung cancer with erlotinib. Two clinical 
      cases.
PG  - S43-51
LID - S0873-2159(15)30321-4 [pii]
LID - 10.1016/S0873-2159(15)30321-4 [doi]
AB  - Early studies with tirosine kinase inhibitors (TKI), namely Erlotinib and 
      Gefitinib, in patients with non small cell lung cancer (NSCLC), showed that 
      although most patients did not respond radiologically, a small percentage of 
      those patients (about 10%) had an excellent response to treatment, with 
      radiological regression and clinical response duration. Four patient populations 
      are known as having better response to TKI as opposed to other patients: 
      adenocarcinoma patients, non-smokers, women and asians. Nevertheless, a good 
      general status remains a predictive factor for treatment response. The discovery 
      of the EGFR mutation in NSCLC patients' tumors and its association with clinical 
      response to Erlotinib and Gefitinib, confirmed by a considerable number of 
      retrospective and prospective studies, showed that response rates are between 
      75-80% in patients carrying this mutation. Although several mutations have been 
      identified, the two commonest (approximately 90%) are located in exons 19 and 21. 
      The authors present two patients studied and treated at the Pulmonology 
      Department's Lung Oncology Unit of CHVNGaia, where Erlotinib was used as 3(rd) 
      line treatment: in one patient, which was part of the population with good 
      response to TKI, a classic exon 19 was identified, and was treated with Erlotinib 
      for twenty months with clinical stability; the other patient did not belong to 
      the above mentioned population and an Exon 20 mutation was identified (a mutation 
      not yet described in literature, being not clear its association with response to 
      treatment with TKI) - treatment was stopped after 7.4months due to disease 
      progression. Rev Port Pneumol 2008; XIV (Supl 3): S43-S51.
CI  - (c) 2008 Sociedade Portuguesa de Pneumologia/SPP.
FAU - Parente, Barbara
AU  - Parente B
AD  - Chefe de Servico de Pneumologia, Trabalho realizado na Unidade de Pneumologia 
      Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila Nova de Gaia. 
      Electronic address: barbaraparente@gmail.com.
FAU - Gomes, Joana
AU  - Gomes J
AD  - Interna do Internato Complementar de Pneumologia, Trabalho realizado na Unidade 
      de Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Nogueira, Carla
AU  - Nogueira C
AD  - Interna do Internato Complementar de Pneumologia, Trabalho realizado na Unidade 
      de Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Ferreira, Diva
AU  - Ferreira D
AD  - Assistente Hospitalar de Pneumologia, Trabalho realizado na Unidade de 
      Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Neves, Sofia
AU  - Neves S
AD  - Assistente Hospitalar de Pneumologia, Trabalho realizado na Unidade de 
      Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Barroso, Ana
AU  - Barroso A
AD  - Assistente Hospitalar de Pneumologia, Trabalho realizado na Unidade de 
      Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Conde, Sara
AU  - Conde S
AD  - Assistente Hospitalar de Pneumologia, Trabalho realizado na Unidade de 
      Pneumologia Oncologica do Servico de Pneumologia do Centro Hospitalar de Vila 
      Nova de Gaia.
FAU - Machado, Jose Carlos
AU  - Machado JC
AD  - Investigador do Instituto de Patologia e Imunologia Molecular da Universidade do 
      Porto (IPATIMUP), Trabalho realizado na Unidade de Pneumologia Oncologica do 
      Servico de Pneumologia do Centro Hospitalar de Vila Nova de Gaia.
LA  - eng
LA  - por
PT  - Journal Article
TT  - Erlotinib no tratamento do carcinoma pulmonar de nao pequenas celulas, doenca 
      avancada. A proposito de dois casos clinicos.
PL  - Spain
TA  - Rev Port Pneumol
JT  - Revista portuguesa de pneumologia
JID - 9813736
OTO - NOTNLM
OT  - Cancro do pulmao de nao pequenas celulas
OT  - Non small cell lung cancer
OT  - epidermal growyh factor receptor
OT  - erlotinib
OT  - receptor do factor de crescimento epidermico
EDAT- 2008/10/01 00:00
MHDA- 2008/10/01 00:01
CRDT- 2015/05/14 06:00
PHST- 2015/05/14 06:00 [entrez]
PHST- 2008/10/01 00:00 [pubmed]
PHST- 2008/10/01 00:01 [medline]
AID - S0873-2159(15)30321-4 [pii]
AID - 10.1016/S0873-2159(15)30321-4 [doi]
PST - ppublish
SO  - Rev Port Pneumol. 2008 Oct;14 Suppl 3:S43-51. doi: 10.1016/S0873-2159(15)30321-4.